Home » Cerulean Doses First Patient in Phase II Study of CRLX101 Drug
Cerulean Doses First Patient in Phase II Study of CRLX101 Drug
Cerulean Pharma has dosed the first patient in a Phase II study of its investigational CRLX101 drug, designed for the treatment of extensive-stage small cell lung cancer patients sensitive to first-line platinum-based chemotherapy.
Pharmaceutical Business Review
Pharmaceutical Business Review
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May